5-羟甲基胞嘧啶与肿瘤  

5-Hydroxymethylcytosine and tumor

作　　者：刘双庆 车德海(综述)[1] 孟庆威(审校)[1] LIU Shuangqing;CHE Dehai;MENG Qingwei(Department of Medicine Oncology,Harbin Medical University Cancer Hospital,Harbin 150086,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院内六科,哈尔滨150086

出　　处：《实用肿瘤学杂志》2021年第4期386-390,共5页Practical Oncology Journal

摘　　要：肿瘤的发生发展和侵袭与表观遗传学变化紧密相关。胞嘧啶甲基化产物5-甲基胞嘧啶(5-methylcytosine,5-mC)是重要的表观遗传学调控因子。羟甲基化是5-mC去甲基化的重要过程之一,其产物5-羟甲基胞嘧啶(5-hydroxy-methylcytosine,5-hmC)也参与基因的表观遗传学调控。国内外研究提示,5-hmC表达水平及分布的改变与胚胎发育、肿瘤发生发展等密切相关。本文对5-hmC及其在肿瘤中的异常与肿瘤关系的研究进展进行综述。The occurrence,development and invasion of tumors are closely related to epigenetic changes.5-Methylcytosine(5-mC),a product of cytosine methylation,is an important epigenetic regulator.Hydroxymethylation is one of the important processes of 5-mC demethylation,and its product 5-hydroxymethylcytosine(5-hmC)is also involved in the epigenetic regulation of genes.Multiple studies at domestic and foreign suggest that the changes of 5-hmC level and distribution are closely related to embryonic development and tumorigenesis.This article reviews the research progress of 5-hmC and its abnormality in tumor and its relationship with tumor.

关 键 词：肿瘤 DNA羟甲基化 5-hmC 

分 类 号：R730.43[医药卫生—肿瘤]